deepLive™ receives new EU MDR CE mark Class IIA
March 2023
deepLive™ is one of the first to receive Class IIA CE mark under EU MDR regulations.
deepLive™ is now CE marked for the management of equivocal basal cell carcinoma lesions with clinical benefits for patients including avoidance of unnecessary and invasive biopsy or surgery.
Check out the Press Release